Weekly Pulse Digest — Edition 35 — May 24, 2026

Published · Researched 2026-09-22

The week in one paragraph

Pulmonary arterial hypertension is a relentlessly progressive disease — the heart fails against diseased lung arteries, and options have been thin. Winrevair changed that. Approved by the FDA in March 2024 as the first activin-signaling inhibitor for PAH, it put up numbers that are hard to argue with: in the pivotal STELLAR trial, patients walked 41 meters farther in the six-minute walk test and had an 84% lower risk of death or clinical worsening compared with background therapy alone. Then a second trial, ZENITH, was stopped early for overwhelming efficacy — a 76% reduction in major morbidity and mortality — earning the drug an expanded label in October 2025, the first clinical-benefit label update in PAH history. Two trials, a new drug class, measured mortality benefit: a landmark for a disease that needed one.

Rising

Community builds, delivered early. On August 6, 2026, Maine's Eastern Trail Alliance and the towns of Scarborough and South Portland cut the ribbon on a 1.6-mile segment that closes a longstanding gap — creating 16 continuous off-road miles from Bug Light to downtown Saco, finished roughly 15 months ahead of schedule, with grants from the Avangrid Foundation and Central Maine Power. The celebration included a community walk-and-ride on the trail itself. Meanwhile in Hornell, New York, a Veterans Wall at Veterans Memorial Park was dedicated on July 3, 2026 — built by donated materials, labor, equipment and money from contractors, the city DPW, veterans, businesses and residents, led by Air Force veteran Henry "Heinz" Pollinger, right on the July 3 deadline. The city formally recognized him that September.
Cubs back in the woods. Two orphaned black bear cubs rehabilitated at the Wildlife Center of Virginia were released back into the wild in spring 2026, the center confirming both cubs' recovery. Simple, complete, done.

Falling

The "public works always run late" narrative. The Eastern Trail finished 15 months early; the Hornell wall landed on a hard July 3 deadline built entirely from donated everything. Two completed promises, on time or better.
PAH as a one-way street. A new drug class that cuts the risk of death or worsening by 84% — then reproduces the mortality benefit in a second trial — reverses what this disease has meant for patients.

Quiet signals

Winrevair's social layer. Strong health-press circulation around the approval and label expansion, but targeted Threads searches returned no direct story posts this session — the social layer is health media rather than viral patient posts, and the tier can't be finalized until direct posts are observed. Thin signal; still watching.
Eastern Trail's price tag. The total project cost and full donor list weren't captured; the Business Wire host was unreachable at the final check, though the ribbon-cutting date, segment length and 16-mile connection are corroborated by reachable family-media and municipal coverage. Still watching.
Hornell's project cost. Same gap: total cost and final donor list not captured; the Evening Tribune host was unreachable, with the July 3 dedication and community-built nature corroborated by Hornell Sun and WLEA. Still watching.
The Virginia cubs' release site. The release location is withheld by convention for wildlife protection — noted, not a gap to chase.

Scoreboard

N/A — editions written out of sequence; no prior calls to grade.

One-line close: Sixteen miles of trail finished early, a wall built on donated everything, two cubs home, and a drug that finally moves a deadly disease backward.